Biarritz

Researchers are evaluating the effect of a triple therapy inhaler called BGF MDI containing budesonide, glycopyrronium, and formoterol fumarate compared with a dual therapy inhaler called GFF MDI containing glycopyrronium and formoterol fumarate in people with Chronic Obstructive Pulmonary Disease (COPD) who have a higher risk of heart and lung problems. This Phase III randomized, double-blind, parallel group study takes place at multiple centers and focuses on cardiopulmonary outcomes in these patients. Participants receive either the BGF MDI 320/14.4/9.6 micrograms twice daily or the GFF MDI 14.4/9.6 micrograms twice daily. The treatments are inhaled using metered dose inhalers. The study compares these two therapies over time to see how they affect the time until the first severe heart or lung event occurs. The study design ensures that neither participants nor researchers know which treatment is given to reduce bias. During the study, participants will have regular visits to the study site or virtual visits to complete assessments. Researchers will monitor lung function, symptoms, and blood tests, including blood eosinophil counts and COPD assessment test scores. The main outcome measured is the time to the first severe cardiac or COPD event, with follow-up lasting up to three years. Safety and adherence to treatment will also be closely observed throughout the study period.

Researchers are investigating a personalized follow-up approach to prevent type 2 diabetes in adults. Type 2 diabetes is a common metabolic disease often diagnosed between ages 40 and 50, with lifestyle factors like poor diet and low physical activity being major risks. Many adults with diabetes remain undiagnosed due to the silent nature of the disease, and early signs may appear up to 20 years before diagnosis. This study explores a preventive management strategy instead of a curative one, given the high medical and economic burden of diabetes in France. Participants will receive support through contact every 4 months with a dedicated study nurse as part of the behavioral intervention. This personalized follow-up aims to help manage risk factors and monitor health over time. The study is designed for adults with an elevated FINDRISC score, a tool used to assess diabetes risk. During the study, participants will be evaluated using the FINDRISC score over a five-year period to measure diabetes risk. Researchers will monitor participants' health and adherence to the follow-up plan. The study involves ongoing assessments to understand the effectiveness of personalized nursing support in preventing the onset of type 2 diabetes.

Researchers are conducting a French prospective observational study to understand how patients aged 18 years and older with moderate to severe atopic dermatitis (AD) are managed when eligible for or currently receiving systemic therapy. The study aims to describe treatment patterns, including previous and current therapies, and monitor drug survival and compliance over time. Experienced dermatologists in hospital and office settings will participate, ensuring treatment decisions reflect real-world clinical practice. Patients will be followed for one year under routine care, with systemic treatment decisions made solely by their physicians independent of study enrollment. The study does not involve specific interventions or changes in treatment but observes the use and management of systemic therapies for AD, including topical corticosteroid use and other systemic options. Participants will complete questionnaires and undergo assessments at baseline, six months, and twelve months. Researchers will collect data on previous and current treatments, therapeutic management of atopic comorbidities, drug survival changes, and treatment adherence. The study focuses on gathering real-life information on systemic therapy use and patient outcomes over the 12-month follow-up period.

Researchers are evaluating the rate at which patients return to sports activities at least three years after receiving a total knee prosthesis. The study compares three different types of knee prostheses—medial pivot, medial bearing, and cruciate retaining—in patients treated between 2018 and 2020. This ambispective, open, and non-randomized study is conducted at a single center and focuses on knee arthropathy patients who have undergone knee replacement surgery. Participants are grouped based on the type of total knee prosthesis they received: medial pivot (Evolution®), mobile bearing (SCORE® Amplitude), or traditional cruciate retaining (Stryker® Triathlon). All surgeries used a conventional alignment technique and the same surgical method. The study involves contacting eligible patients, explaining the study details, and obtaining oral consent. Assessments include telephone evaluations and electronic questionnaires about functional and physical abilities, which patients can return via email or phone. Throughout the study, patients will provide information regarding their return to sport and physical function after their knee replacement. The primary outcome measured is the rate of return to sport three years after surgery. The investigators will monitor responses through secure communication and document inclusion in medical records. This study aims to better understand the long-term outcomes of different prosthesis designs on patients' sports activity resumption.

This research aims to monitor the long-term performance of the FX SHOULDER SOLUTIONS shoulder systems used for shoulder replacement surgeries. It includes patients with conditions such as proximal humeral fracture, glenohumeral osteoarthritis, avascular necrosis of the humerus head, rotator cuff tear or arthropathy, inflammatory arthritis, and revision of a shoulder prosthesis. The study's main goal is to assess the revision rate of these shoulder systems over a 10-year period after surgery, providing real-world data on their durability and outcomes. Participants undergo total anatomical, hemi anatomical, or reversed shoulder arthroplasties using the FX SHOULDER SOLUTIONS systems. The study includes 1004 cases divided into 11 implant groups based on range, indication, and implant constructs. Patients may be included retrospectively or prospectively, with a preference for prospective enrollment. Follow-up visits are scheduled at 6 weeks, 3 or 6 months, 1, 2, 3, 5, 7, and 10 years after surgery to monitor progress and outcomes. During the study, researchers collect data on revision rates, range of motion, various shoulder function scores (Quick Dash, Constant, ASES, SSV), pain levels, and radiological assessments of implant positioning at each visit. They also track complications and gather qualitative feedback from surgeons about the surgical instruments used. This comprehensive approach helps evaluate the long-term success and safety of the shoulder systems, with a total participation duration of 10 years post-surgery.